Literature DB >> 16221223

Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.

Prabath W B Nanayakkara1, Tom Teerlink, Coen D A Stehouwer, Daud Allajar, Annemieke Spijkerman, Casper Schalkwijk, Piet M ter Wee, Coen van Guldener.   

Abstract

BACKGROUND: Patients with renal insufficiency have an increased risk of cardiovascular disease that is not fully explained by the presence of known cardiovascular risk factors. In patients with end-stage renal disease, increased serum concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), has been linked to excess cardiovascular morbidity. We investigated, in patients with mild-to-moderate renal failure, the relationship between plasma ADMA and three surrogate markers of atherosclerosis that have been shown to have prognostic value, namely carotid intima-media thickness (IMT), plasma soluble vascular cell adhesion molecule-1 (sVCAM-1), and plasma C-reactive protein (CRP).
METHODS: We used baseline data of an ongoing randomized trial in which the effects of oxidative stress-lowering treatment on vascular function and structure are studied in patients with chronic nondiabetic renal failure without clinical evidence of atherosclerosis (GFR 15 to 70 mL/min/per 1.73 m(2) according to the Cockcroft-Gault equation; ATIC study).
RESULTS: Data from 93 patients were used. Creatinine clearance was inversely related to plasma ADMA concentration (standardized beta after adjustment = -0.342, P = 0.023). Plasma ADMA was strongly related to carotid IMT in univariate (beta = 0.459, P < 0.0001) and multivariate analysis (beta= 0.444, P < 0.0001). Plasma ADMA was also significantly related with plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) in univariate (beta = 0.260, P = 0.010) and multivariate (beta = 0.242, P = 0.022) analysis. Plasma ADMA was not significantly related to C-reactive protein (beta = -0.134, P = 0.204).
CONCLUSION: In patients with mild-to-moderate renal failure, renal function is inversely associated with plasma ADMA, which, in turn, is positively associated with carotid IMT and plasma sVCAM-1 concentration. Increased plasma ADMA may be a link between renal function and cardiovascular disease in patients with mild-to-moderate renal failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221223     DOI: 10.1111/j.1523-1755.2005.00680.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  24 in total

1.  ADMA levels and arginine/ADMA ratios reflect severity of disease and extent of inflammation after subarachnoid hemorrhage.

Authors:  Cecilia Lindgren; Magnus Hultin; Lars-Owe D Koskinen; Peter Lindvall; Ljubisa Borota; Silvana Naredi
Journal:  Neurocrit Care       Date:  2014-08       Impact factor: 3.210

Review 2.  Essential hypertension and oxidative stress: New insights.

Authors:  Jaime González; Nicolás Valls; Roberto Brito; Ramón Rodrigo
Journal:  World J Cardiol       Date:  2014-06-26

Review 3.  The role of asymmetric and symmetric dimethylarginines in renal disease.

Authors:  Edzard Schwedhelm; Rainer H Böger
Journal:  Nat Rev Nephrol       Date:  2011-03-29       Impact factor: 28.314

Review 4.  Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome.

Authors:  Paolo C Colombo; Anjali Ganda; Jeffrey Lin; Duygu Onat; Ante Harxhi; Julia E Iyasere; Nir Uriel; Gad Cotter
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

5.  ADMA injures the glomerular filtration barrier: role of nitric oxide and superoxide.

Authors:  Mukut Sharma; Zongmin Zhou; Hiroto Miura; Andreas Papapetropoulos; Ellen T McCarthy; Ram Sharma; Virginia J Savin; Elias A Lianos
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-18

6.  Atheroma progression in chronic kidney disease.

Authors:  Claudio Rigatto; Adeera Levin; Andrew A House; Brendan Barrett; Euan Carlisle; Adrian Fine
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 8.237

7.  Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort.

Authors:  Renke Maas; Vanessa Xanthakis; Joseph F Polak; Edzard Schwedhelm; Lisa M Sullivan; Ralf Benndorf; Friedrich Schulze; Ramachandran S Vasan; Philip A Wolf; Rainer H Böger; Sudha Seshadri
Journal:  Stroke       Date:  2009-06-04       Impact factor: 7.914

8.  Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

Authors:  Jill Melendez Young; Norma Terrin; Xuelei Wang; Tom Greene; Gerald J Beck; John W Kusek; Allan J Collins; Mark J Sarnak; Vandana Menon
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 8.237

Review 9.  Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.

Authors:  Johannes Jacobi; Philip S Tsao
Journal:  Am J Nephrol       Date:  2007-10-24       Impact factor: 3.754

10.  Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS).

Authors:  Minesh Khatri; Clinton B Wright; Thomas L Nickolas; Mitsuhiro Yoshita; Myunghee C Paik; Grace Kranwinkel; Ralph L Sacco; Charles DeCarli
Journal:  Stroke       Date:  2007-10-25       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.